What is BridgeBio Pharma, Inc. (BBIO) stock price today?

BridgeBio Pharma, Inc. (BBIO) is currently trading at $65.04, down 2.2% today.

What is BBIO P/E ratio?

BridgeBio Pharma, Inc.'s P/E ratio is -18.58. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BBIO return on equity (ROE)?

BridgeBio Pharma, Inc.'s return on equity (ROE) is 31.67%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is BridgeBio Pharma, Inc.'s market cap?

BridgeBio Pharma, Inc. has a market capitalization of $12.74B.

NASDAQ · Biotechnology

BridgeBio Pharma, Inc. (BBIO) Stock

$65.04 -2.20% NASDAQ: BBIO Healthcare

Valuation

Metric	Value
Price	$65.04
Market Cap	$12.74B
P/E Ratio	-18.58
P/B Ratio	-5.18
P/S Ratio	18.27
EPS (TTM)	$0.00
52-Week High	$93.42
52-Week Low	$52.75
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	31.67%
ROA	-57.20%
ROCE	-166.38%
Gross Margin	-113.35%
Operating Margin	-113.35%
Net Margin	-97.64%
Debt/Equity	-0.99
Current Ratio	2.62

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$70.0M	$78.0M	$9.0M	$222.0M	$502.0M
Operating Profit	$-577.0M	$-512.0M	$-607.0M	$-593.0M	$-569.0M
Net Profit	$-563.0M	$-481.0M	$-643.0M	$-536.0M	$-729.0M
EPS	$-3.90	$-3.35	$-3.95	$-2.88	$-3.79
Op Margin	-827.1%	-659.6%	-6528.8%	-267.2%	-113.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.0B	$623.0M	$546.0M	$919.0M	$936.0M
Total Liabilities	$1.9B	$1.9B	$1.9B	$2.4B	$3.0B
Cash	$394.0M	$377.0M	$376.0M	$681.0M	$570.0M
Borrowings	$1.7B	$1.7B	$1.7B	$1.7B	$2.7B

Latest News

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo Zacks · Jul 14, 2026 The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions MarketBeat · Jul 13, 2026 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026 How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High Zacks · Jul 10, 2026 Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? Trefis · Jul 10, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-498.0M	$-419.0M	$-528.0M	$-521.0M	$-446.0M
Investing Cash Flow	$-249.0M	$447.0M	$53.0M	$60.0M	$-26.0M
Financing Cash Flow	$-343.0M	$3.0M	$2.0M	$-43.0M	$-60.0M
Net Cash Flow	$38.0M	$21.0M	$-22.0M	$289.0M	$-111.0M
Free Cash Flow	$-546.0M	$-426.0M	$-529.0M	$-522.0M	$-447.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-1.44
EV / EBITDA	-24.62
FCF Yield	-3.38%
Quick Ratio	1.17
Interest Coverage	-6.05
Return 1Y	22.61%
Return 3Y	165.08%
Return 5Y	49.63%

Ownership

Insiders Held3.92%

Institutions Held102.01%

Institutions Float Held106.17%

Institutional Holder	Shares	Report Date
Blackrock Inc.	14,207,757	2026-03-31
Kohlberg Kravis Roberts & Co. L.P.	13,260,971	2026-03-31
Janus Henderson Group PLC	13,179,013	2026-03-31
Viking Global Investors, L.P.	11,842,434	2026-03-31
Farallon Capital Management LLC	9,365,463	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALNYAlnylam Pharmaceuticals, Inc.	$224.53	+0.05%	36.02	$30.04B	0.00%
ASNDAscendis Pharma A/S - Ordinary Share	$222.69	-2.50%	16.85	$13.83B	0.00%
BMRNBioMarin Pharmaceutical Inc.	$54.89	-0.56%	151.42	$10.61B	0.00%
DNLIDenali Therapeutics Inc.	$18.67	-2.56%	-7.04	$2.96B	0.00%
IONSIonis Pharmaceuticals, Inc.	$43.30	-1.95%	-12.57	$7.20B	0.00%

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is led by CEO Neil Kumar, employs 839 people, headquartered in Palo Alto, US, publicly traded since 2019.

BridgeBio Pharma, Inc. (BBIO) stock trades at $65.04 with a market capitalization of $12.74B. The stock is valued at a price-to-earnings (P/E) ratio of -18.58, price-to-book of -5.18, price-to-sales of 18.27. Over the past 52 weeks the stock has ranged between $52.75 and $93.42, and currently trades 30.4% below its 52-week high.

On profitability, BridgeBio Pharma, Inc. generates a return on equity (ROE) of 31.67% — well above the market average, a sign of a high-quality business, return on capital employed of -166.38%, an operating margin of -113.35%, a net profit margin of -97.64%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides